...
首页> 外文期刊>Transplant international : >T cell receptor beta chain (TCR-Vbeta) repertoire of circulating CD4(+) CD25(-), CD4(+) CD25(low) and CD4(+) CD25(high) T cells in patients with long-term renal allograft survival.
【24h】

T cell receptor beta chain (TCR-Vbeta) repertoire of circulating CD4(+) CD25(-), CD4(+) CD25(low) and CD4(+) CD25(high) T cells in patients with long-term renal allograft survival.

机译:长期同种异体肾移植存活患者的循环CD4(+)CD25(-),CD4(+)CD25(低)和CD4(+)CD25(高)T细胞的T细胞受体beta链(TCR-Vbeta)清单。

获取原文
获取原文并翻译 | 示例
           

摘要

The mechanisms underlying maintenance of renal allografts in humans under minimal or conventional immunosuppression are poorly understood. There is evidence that CD4(+) CD25(+) regulatory T cells and clonal deletion, among other mechanisms of tolerance, could play a key role in clinical allograft survival. Twenty-four TCR-Vbeta families were assessed in CD4(+) CD25(-), CD4(+) CD25(low) and CD4(+) CD25(high) T cells from patients with long-term renal allograft survival (LTS), patients exhibiting chronic rejection (ChrRx), patients on dialysis (Dial) and healthy controls (HC) by flow cytometry. LTS patients presented a higher variability in their TCR-Vbeta repertoire, such decreased percentage of Vbeta2(+), Vbeta8a(+) and Vbeta13(+) in CD4(+) CD25(low) and (high) compared with CD4(+) CD25(-) subset and increased Vbeta4 and Vbeta7 families in CD4(+) CD25(high) T cells exclusively. Additionally, LTS patients, particularly those that were not receiving calcineurin inhibitors (CNI), had increased percentages of CD4(+) CD25(high) T cells when compared with Dial (P < 0.05) and ChrRx (P < 0.05) patients. Our results suggest that a differential expression of particular TCR-Vbeta families and high levels of circulating CD4(+) CD25(high) T cells in long-term surviving renal transplant patients could contribute to an active and specific state of immunologic suppression. However, the increase in this T cell subset with regulatory phenotype can be affected by CNI.
机译:在最小或常规免疫抑制下维持人类同种异体肾移植的基本机制了解甚少。有证据表明,CD4(+)CD25(+)调节性T细胞和克隆缺失以及其他耐受机制可能在同种异体移植临床存活中起关键作用。对来自长期肾移植存活期(LTS)患者的CD4(+)CD25(-),CD4(+)CD25(低)和CD4(+)CD25(高)T细胞中的24个TCR-Vbeta家族进行了评估,表现出慢性排斥反应(ChrRx)的患者,接受透析的患者(Dial)和通过流式细胞仪进行的健康对照(HC)。 LTS患者的TCR-Vbeta曲目具有较高的变异性,与CD4(+)相比,CD4(+)CD25(低)和(高)中Vbeta2(+),Vbeta8a(+)和Vbeta13(+)的百分比降低CD25(-)子集和增加的CD4(+)CD25(high)T细胞中的Vbeta4和Vbeta7家族。此外,与Dial(P <0.05)和ChrRx(P <0.05)患者相比,LTS患者,尤其是未接受钙调神经磷酸酶抑制剂(CNI)的患者,其CD4(+)CD25(高)T细胞百分比更高。我们的结果表明,在长期存活的肾移植患者中,特定TCR-Vbeta家族的差异表达和高水平的循环CD4(+)CD25(高)T细胞可能有助于免疫抑制的活跃和特定状态。但是,这种具有调节表型的T细胞亚群的增加可能会受到CNI的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号